Abstract 427P
Background
Several important factors affect directly or indirectly the quality of life of women with cancer in India. Several unmet needs were found to be unaddressed. This program aims to empower the patient, improve quality of life and encourage them to actively participate in the healing process. Hospitals and oncologists are challenged to develop programs that support the growing number of cancer patients. Failure to address leads to decreased compliance and outcomes.
Methods
Patients will be enrolled to participate in the introductory half a day program after obtaining informed consent and completing the pre assessment form (physical, psychological and socio-economic domains, along with demography, diagnosis and details of treatment received). Program deals with confidence building tips on grooming, Skin and hair care, management of external prosthesis and wigs, lymphedema prevention, Nutritional advice, De-stressing and relaxation techniques Functional exercises for fitness and rehabilitation through supervised fitness and restorative yoga practices. Following the introductory program women are invited to join the 5 day session. The main intervention during this period is supervised yoga, motivation and counseling, meditative practices, guided relaxation, music, dance therapy. The tools used for assessment pre and post intervention are the assessment questionnaire and Hospital Anxiety and Depression (HADS) scale. Many of the physical problems in these women led to emotional problems such as anxiety and depression hence the HADS scale was used.
Results
370 patients were enrolled in the study-86% of patients had breast cancer. Age ranged between 26-76 years. 75% of patients were below 60 years. 18% of the patients below 40 years had breast cancer. The burden of unmet needs was primarily issues related to appearance, hair loss, skin changes, body image, arm swelling, impairment of cognitive factors and emotional problems like depression, anxiety and worry. The percentage of patients with anxiety and depression pre and post interventionTable:
427P
HADS DEPRESSION SCORE | PRE-INTERVENTION | POST-INTERVENTION |
---|---|---|
BORDER LINE (8-10) | 12.50% | 0% |
ABNORMAL (11-21) | 12.50% | 0% |
HADS ANXIETY SCORE | PRE-INTERVENTION | POST-INTERVENTION |
BORDER LINE (8-10) | 18.80% | 0% |
ABNORMAL (11-21) | 37.50% | 0% |
Conclusions
This preliminary study shows that such unique, multidimensional supportive care programs have a significant impact on quality of life through treatment into survivorship phase.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P.P. Bapsy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract